DOSE DENSE HIGH DOSE METHYLPREDNISOLONE (HDMP) AND RITUXIMAB (RTX) ARE EFFECTIVE IN RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION (17P DEL) / TP53 MUTATION

被引：0
|
作者：
Pileckyte, R. [1 ]
Valceckiene, V. [1 ]
Zvirblis, T. [1 ]
Griskevicius, L. [1 ]
机构：
[1] Vilnius Univ Hosp Santariskiu Clin, Vilnius, Lithuania
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1294
引用
收藏
页码：525 / 526
页数：2
相关论文
共 50 条
  • [21] Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
    Montserrat, Emili
    Dreger, Peter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 : S74 - S81
  • [22] NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation
    Mikudina, Boglarka
    Goodall, Melinda
    Adler, Amanda I.
    LANCET ONCOLOGY, 2017, 18 (03): : 289 - 290
  • [23] Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia
    Salem, Ahmed Hamed
    Dunbar, Martin
    Agarwal, Suresh K.
    ANTI-CANCER DRUGS, 2017, 28 (08) : 911 - 914
  • [24] Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia
    Mannis, Gabriel
    Wu, Davina
    Dea, Tiffany
    Mauro, Theodora
    Hsu, Gerald
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (02) : 179 - 179
  • [25] Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harbouring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation)
    Cramer, Paula
    von Tresckow, Julia
    Bahlo, Jasmin
    Robrecht, Sandra
    Tausch, Eugen
    Fuerstenau, Moritz
    Langerbeins, Petra
    Al-Sawaf, Othman
    Fink, Anna-Maria
    Fischer, Kirsten
    Wendtner, Clemens-Martin
    Eichhorst, Barbara
    Kneba, Michael
    Stilgenbauer, Stephan
    Hallek, Michael
    BLOOD, 2018, 132
  • [26] INCIDENCE OF 17P DELETION AND TP53 MUTATION IN MYELODYSPLASTIC SYNDROME AND ACUTE LEUKEMIA WITH 5Q DELETION.
    Eclache-Saudreau, V.
    Sebaa, A.
    Ades, L.
    Baran-Marszak, F.
    Mozziconacci, M. J.
    Dobbelstein, S.
    Penther, D.
    Stamatoullas, A.
    Prebet, T.
    Rechet, C.
    Fenaux, P.
    HAEMATOLOGICA, 2012, 97 : 136 - 136
  • [27] Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation
    Buccheri, Valeria
    Barreto, Wolney Gois
    Fogliatto, Laura Maria
    Capra, Marcelo
    Marchiani, Mariana
    Rocha, Vanderson
    ANNALS OF HEMATOLOGY, 2018, 97 (12) : 2269 - 2278
  • [28] Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation
    Valeria Buccheri
    Wolney Gois Barreto
    Laura Maria Fogliatto
    Marcelo Capra
    Mariana Marchiani
    Vanderson Rocha
    Annals of Hematology, 2018, 97 : 2269 - 2278
  • [29] Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia*
    Davids, Matthew S.
    Kim, Haesook T.
    Yu, Lijian
    De Maeyer, Guadalupe
    McDonough, Mikaela
    Vartanov, Alexander R.
    Langey, Rachael
    Fernandes, Stacey M.
    Hellman, Jeffrey M.
    Francoeur, Karen
    Arnason, Jon
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Fisher, David C.
    Brown, Jennifer R.
    LEUKEMIA & LYMPHOMA, 2019, 60 (05) : 1312 - 1315
  • [30] Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods
    Chauffaille, Maria de Lourdes L. F.
    Zalcberg, Ilana
    Barrero, Wolney Gois
    Bendit, Israel
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2020, 42 (03) : 261 - 268
12345